Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Chia-Hao Chang, National Taiwan University Hospital, Hsin-Chu, Taiwan; Chih-Hsin Lee, Wangfang Hospital, Taipei Medical University, Taipei, Taiwan; and Jann-Yuan Wang, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Hao
CH
Chang
Chia-Hao Chang, National Taiwan University Hospital, Hsin-Chu, Taiwan; Chih-Hsin Lee, Wangfang Hospital, Taipei Medical University, Taipei, Taiwan; and Jann-Yuan Wang, National Taiwan University Hospital, Taipei, Taiwan.
Chih-Hsin
CH
Lee
Chia-Hao Chang, National Taiwan University Hospital, Hsin-Chu, Taiwan; Chih-Hsin Lee, Wangfang Hospital, Taipei Medical University, Taipei, Taiwan; and Jann-Yuan Wang, National Taiwan University Hospital, Taipei, Taiwan.
Jann-Yuan
JY
Wang
D000077192:Adenocarcinoma of Lung; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms; D011799:Quinazolines
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib